Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Nov 6;27(2):174–178. [Article in German] doi: 10.1007/s00761-020-00868-6

Onkologie und Versorgung in Fach- und Publikumsmedien

Antikörper Pamrevlumab bei radiogen induzierter Lungenfibrose? L-Carnitin und Omega-3-Fettsäuren zur Verhinderung von Kardiotoxizität durch Anthrazykline? Krebsrisiko bei Nachkommen nach Kinderwunschbehandlung? Tumormarker CA 50 beim Pankreaskarzinom – noch relevant? Immunschwäche nach Krebstherapie?

PMCID: PMC7646488  PMID: 33173255

The content is available as a PDF (181.8 KB).

Literatur

  • 1.Giuranno L, et al. Radiation-Induced Lung Injury (RILI) Front Oncol. 2019;9:877. doi: 10.3389/fonc.2019.00877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Fibrogen Inc https://www.fibrogen.com/. Zugegriffen: 16. Okt. 2020
  • 3.Richeldi L, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25–33. doi: 10.1016/S2213-2600(19)30262-0. [DOI] [PubMed] [Google Scholar]
  • 4. ZEPHYRUS Study – FG-3019-091 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF). https://clinicaltrials.gov/ct2/show/NCT03955146. Zugegriffen: 12. Okt. 2020
  • 5.Bickelhaupt S, et al. Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis. Jnci: J Natl Cancer Inst. 2017;109(8):djw339. doi: 10.1093/jnci/djw339. [DOI] [PubMed] [Google Scholar]
  • 6.Sternlicht MD, et al. Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab. Respir Res. 2018;19:14. doi: 10.1186/s12931-018-0720-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.European Medicines Agency (2019) Public summary of opinion on orphan designation. Pamrevlumab for the treatment of Duchenne muscular dystrophy. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3192234. Zugegriffen: 12. Okt. 2020
  • 8.Curigliano G, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–190. doi: 10.1016/j.annonc.2019.10.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Rassaf T, et al. Onkologische Kardiologie. Konsensuspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung, der Deutschen Gesellschaft für Pädiatrische Kardiologie und Angeborene Herzfehler und der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie. Kardiologe. 2020;14:267–293. doi: 10.1007/s12181-020-00395-z. [DOI] [Google Scholar]
  • 10.Appell P, et al. Kardiotoxizität onkologischer Therapien (3): Komplikationen, Prävention und Langzeitüberwachung. Dtsch Arztebl. 2019;116(40):36. doi: 10.3238/PersKardio.2019.10.04.07. [DOI] [Google Scholar]
  • 11.MladÄ›nka P, et al. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018;38(4):1332–1403. doi: 10.1002/med.21476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Serini S, et al. Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review. Int J Mol Sci. 2017;18(E2689):12. doi: 10.3390/ijms18122689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Armenian SH, et al. Carnitine and Cardiac Dysfunction in Childhood Cancer Survivors Treated with Anthracyclines. Cancer Epidemiol Biomarkers Prev. 2014;23(6):1109–1114. doi: 10.1158/1055-9965.EPI-13-1384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.van Dalen EC, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;6:CD003917. doi: 10.1002/14651858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Flanagan J, et al. Role of carnitine in disease. Nutr Metab (Lond) 2010;7:30. doi: 10.1186/1743-7075-7-30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.DiNicolantonio J, et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013;2013(88):544–551. doi: 10.1016/j.mayocp.2013.02.007. [DOI] [PubMed] [Google Scholar]
  • 17.Armenian SH, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911. doi: 10.1200/JCO.2016.70.5400. [DOI] [PubMed] [Google Scholar]
  • 18.Deutsche IVF-Register (D.I.R) e.V. (2019) Jahrbuch 2018. https://www.deutsches-ivf-register.de/jahrbuch.php. Zugegriffen: 16. Okt. 2020
  • 19.Raimondi S, et al. Meta-analysis of cancer incidence in children born after assisted reproductive technologies. Br J Cancer. 2005;93:1053–1056. doi: 10.1038/sj.bjc.6602838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hargreave M, et al. Fertility treatment and childhood cancer risk: a systematic meta-analysis. Fertil Steril. 2013;100:150–161. doi: 10.1016/j.fertnstert.2013.03.017. [DOI] [PubMed] [Google Scholar]
  • 21.Reigstad MM, et al. Literature review on cancer risk in children born after fertility treatment suggests increased risk of haematological cancers. Acta Paediatr. 2017;106(5):698–709. doi: 10.1111/apa.13755. [DOI] [PubMed] [Google Scholar]
  • 22.Wang T, et al. Cancer risk among children conceived by fertility treatment. Int J Cancer. 2019;144(12):3001–3013. doi: 10.1002/ijc.32062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Spaan M, et al. Risk of cancer in children and young adults conceived by assisted reproductive technology. Hum Reprod. 2019 doi: 10.1093/humrep/dey394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hargreave M, et al. Association Between Fertility Treatment and Cancer Risk in Children. JAMA. 2019;322(22):2203–2210. doi: 10.1001/jama.2019.18037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Spector LG, et al. Association of In Vitro Fertilization With Childhood Cancer in the United States. JAMA Pediatr. 2019;01:2019. doi: 10.1001/jamapediatrics.2019.0392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Krebs in Deutschland für 2015/2016. 12. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2019. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_node.html. Zugegriffen: 16. Okt. 2020
  • 27.Shan M, et al. Serum CA50 levels in patients with cancers and other diseases. Prog Mol Biol Transl Sci. 2019;162:187–198. doi: 10.1016/bs.pmbts.2018.12.006. [DOI] [PubMed] [Google Scholar]
  • 28.Holdenrieder S, Stieber P. Carbohydrate antigen 50. In: Gressner AM, Arndt T, editors. Lexikon der Medizinischen Laboratoriumsdiagnostik. Springer Reference Medizin. Berlin, Heidelberg: Springer; 2019. [Google Scholar]
  • 29.Duffy MJ. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21(3):441–447. doi: 10.1093/annonc/mdp332. [DOI] [PubMed] [Google Scholar]
  • 30.Heptner G, et al. Vergleich der Tumormarker CA 50 und CA 19-9 bei benignen und malignen Erkrankungen des oberen Gastrointestinaltraktes [Comparison of CA 50 and CA 19-9 tumor markers in benign and malignant diseases of the upper gastrointestinal tract. Dtsch Med Wochenschr. 1986;111(10):374–378. doi: 10.1055/s-2008-1068458. [DOI] [PubMed] [Google Scholar]
  • 31.Verma R, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016;2016(18):10. doi: 10.1186/s13058-015-0669-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Gustafson CE, et al. Immune cell repertoires in breast cancer patients after adjuvant chemotherapy. JCI Insight. 2020 doi: 10.1172/jci.insight.134569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kang DH, et al. Significant impairment in immune recovery after cancer treatment. Nurs Res. 2009;58(2):105–114. doi: 10.1097/NNR.0b013e31818fcecd. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Mazur B, et al. Decreased numbers of CD41 T lymphocytes in peripheral blood after treatment of childhood acute lymphoblastic leukemia. Leuk Res. 2006;30:33–36. doi: 10.1016/j.leukres.2005.05.024. [DOI] [PubMed] [Google Scholar]
  • 35.Williamson EJ, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Uzzo G et al (2020) Coronavirus disease 2019 (COVID-19): Risks for infection, clinical presentation, testing, and management in patients with cancer. UpTo Date. https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-risks-for-infection-clinical-presentation-testing-and-management-in-patients-with-cancer. Zugegriffen: 16. Okt. 2020
  • 37.Deutsche Gesellschaft für Hämatologie und Onkologie (2020) Onkopedia: Coronavirus-Infektion (COVID-19) bei Patienten mit Blut- und Krebserkrankungen. https://www.onkopedia.com/de/onkopedia/guidelines/coronavirus-infektion-covid-19-bei-patienten-mit-blut-und-krebserkrankungen/@@guideline/html/index.htm. Zugegriffen: 16. Okt. 2020

Articles from Der Onkologe are provided here courtesy of Nature Publishing Group

RESOURCES